Responsible Investments in Life Science.
- We use the UN Sustainable Development Goals (SDGs) as a guideline for what to prioritize.
- In our industry, Goal 3 – “Good Health and Well-being” is most in focus, however, all the goals are interlinked.
- Innovation is the key to achieve UN Health SDG. Investing in the healthcare sector is a way to contribute to the achievement of this goal and a sustainable future.
From the very start of Arctic Aurora LifeScience, our ambition has been to fully integrate sustainability in our investment process. We are convinced that taking material ESG factors into account lowers the risks and improves our investment decisions and hence improves the result for our investors. In addition, we believe that the only viable way for a company to create long-term financial success is to manage its business in a sustainable way.
We invest both in large pharmaceutical companies with large production facilities and more than 100,000 employees as well as small biotechnology companies that are not much more than a lab and a few researchers. These companies face very different challenges, and analyzing them from an ESG perspective requires different approaches. In the case of the large companies, we rely to a large extent on data provided by the companies themselves or external providers, like the Carbon Disclosure Project (CDP).
Our work has resulted in a proprietary check-list suggesting a model for how investors can evaluate biotechnology companies with regards to sustainability. The model focuses on four areas; Innovation Capability, Safe and Ethical Product Development, Corporate Governance and Access to Health, where Innovation Capability is a necessity for a sustainable business and for long-term return on investment.
Please download our full SRI Reports:
- Invest in Arctic Aurora LifeScience - Private Clients (Norwegian only)
- For institutional clients, please contact one of our product specialists
Arctic Aurora LifeScience is an equity fund investing in global biotechnology and pharmaceutical companies. The fund is run by former portfolio manager in the Swedish AP3 Fonder, Ulrica Bjerke, as well as Dr. Torbjørn Bjerke, both with 20 years of experience from the market. Arctic Aurora LifeScience was launched in May 2016 with both hedged and un-hedged share classes.
Past performance in Arctic Aurora LifeScience is no guarantee for future returns. Future returns depend on the market, fund manager skill, fund risk level, costs, among others. Performance in the fund may at times be negative and may for this fund vary considerably within periods.